Entries by Thomas Gabrielczyk

Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal

Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.

Trilogue put lights on green for Horizon Europe

The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliament’s proposal to increase its budget from €100bn to €120bn.

Genfit in $228m deal with Terns Pharmaceuticals

Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor  to Terns Pharmaceuticals Inc.
                                                                           

Researchers and bioethicists to pause germline editing

After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.